Patient information | Â | Characterization & anti-tumor efficacy in the Patient-derived EC xenograft models | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | HER-2 | Mutation | Trastuzumab efficacy | ||||||||||
Gender/age | Pathology | TNM stage | Grade | Model ID | FISH GCN | FISH Ratio (HER-2/CEP17) | IHC | PIK3CA | EGFR | K-ras | B-raf | TGI% | Tumor regression % | P value |
M/70 | ESCC | IIIB | Moderate | EC004 | 1.52 | 1.07 | - | - | - | - | - | 44 | 0 | 0.1333 |
M/61 | ESCC | IIA | Poor | EC016 | 2.38 | 1.25 | - | - | - | - | - | 0 | 0 | 0.3113 |
M/65 | ESCC | IIA | Moderate | EC039 | 3.92 | 1.26 | ++ | + | - | - | - | 41 | 0 | 0.2290 |
M/56 | ESCC | IIIA | Moderate | EC044 | 3.90 | 1.55 | ++ | - | - | - | - | >100 | 93 | <0.0001 |
M/73 | ESCC | IIIA | Moderate | EC054 | 3.04 | 1.27 | - | - | - | - | - | 48 | 0 | 0.0004 |